The Drug That Treats SMA by Ignoring the Root Cause
The FDA just approved the first SMA drug that ignores the broken gene entirely and goes straight to the muscle. Scholar Rock's Isembyld succeeded where a generation of myostatin inhibitors failed, and the story of how is more interesting than you'd expect.
A New Playbook for an Old Disease
For nearly a decade, every approved treatment for spinal muscular atrophy (SMA) has tried to fix the same thing: a broken gene. Those therapies boost production of a protein called SMN that keeps motor neurons alive. They've changed lives. But they haven't finished the job.
Patients on these treatments still lose muscle function over time. They still struggle with everyday movements. The neurons get help; the muscles don't.
On September 11, the FDA flipped that script. It approved Isembyld (apitegromab-mstn), a monthly infusion from Scholar Rock that treats SMA by targeting the muscle itself. It's the first drug of its kind, and it works alongside existing gene-focused therapies rather than replacing them. Think of it like this: if existing treatments keep the electrical wiring intact, Isembyld upgrades the appliances plugged into it.
The approval covers adults and children aged 2 and older who are already on an SMN2-targeted therapy. Scholar Rock also picked up a Rare Pediatric Disease Priority Review Voucher, a transferable golden ticket that can shave months off a future FDA review (and sells on the open market for hundreds of millions of dollars).
How You Fight a Disease From the Other Direction
Your body produces a protein called myostatin that acts like a governor on an engine. It caps how much your muscles can grow. In healthy people, that's fine. In SMA patients whose muscles are already wasting away, it's a problem.
Apitegromab is a monoclonal antibody that grabs onto the inactive precursor forms of myostatin (called promyostatin and latent myostatin) before they can be converted into the active, muscle-suppressing version. It's essentially removing the speed limiter so weakened muscles have a better shot at growing and functioning.
This is fundamentally different from the three existing SMA therapies: nusinersen (Spinraza), approved in 2016 as an antisense oligonucleotide; risdiplam (Evrysdi), an oral solution approved in 2020; and , a one-time gene replacement therapy. All three focus on motor neurons. Apitegromab doesn't touch SMN protein levels at all. It goes straight to the muscle.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
onasemnogene abeparvovec (Zolgensma)
That complementary mechanism is the whole point. Scholar Rock designed it to be layered on top of what patients are already taking, not to compete with it.
The Trial That Got It Done
The FDA's decision rested primarily on SAPPHIRE, a Phase 3 study supported by data from two earlier trials called TOPAZ and ONYX.
In SAPPHIRE, patients aged 2 to 12 on background SMA therapy received either apitegromab or placebo. Researchers measured motor function using the Hammersmith Functional Motor Scale Expanded (HFMSE), a standardized test that scores physical abilities like sitting, standing, and walking. Higher scores mean better function.
The combined treatment group (pooling the 10 mg/kg and 20 mg/kg doses) beat placebo by 1.8 points on the HFMSE scale. That might sound modest until you consider the context: in a disease where patients are fighting to maintain the function they have, any upward movement is meaningful. The result was statistically significant (p=0.019).
But the more striking numbers came from the responder analysis. About 30% of patients on apitegromab gained 3 or more points on the scale, compared to just 12.5% on placebo. Nearly 20% gained 4 or more points, versus 6.3% on placebo. Improvements showed up as early as 8 weeks and held steady through the full 52-week study.
One interesting wrinkle: the 10 mg/kg dose actually outperformed the higher 20 mg/kg dose, with a 2.2-point advantage over placebo compared to 1.4 points. The higher dose didn't reach statistical significance on its own. Biology doesn't always follow a "more is better" rule.
The Graveyard of Myostatin Drugs
If you're thinking "blocking myostatin sounds too good to be true," you're not wrong to be skeptical. This idea has been around since 1997, and the path here is littered with expensive failures.
Stamulumab (MYO-029) was the first myostatin inhibitor to reach human trials. It was safe enough, but it didn't actually make patients stronger. Development stopped. Domagrozumab tried the same concept in Duchenne muscular dystrophy. Patients gained some lean mass, but it didn't translate into functional improvement. Killed. ACE-031 went after the broader TGF-β pathway and got pulled after patients started bleeding from their gums and noses; it was hitting vascular targets nobody wanted it to hit.
The pattern was brutal: these drugs could change what muscles looked like without changing what muscles did.
So why did apitegromab break through? Two reasons stand out.
First, selectivity. Older drugs blocked myostatin broadly or hit related proteins in the TGF-β family, causing off-target problems. Apitegromab only binds the inactive precursor forms, which narrows its effects to skeletal muscle without the collateral damage.
Second, disease context. Earlier failures mostly targeted muscular dystrophies where muscle tissue is already severely damaged and scarred. SMA is different. The muscles aren't inherently broken; they're withering because the nerve signals aren't getting through properly. Combine a therapy that fixes the nerve signaling (existing SMN treatments) with one that supports the muscle downstream (apitegromab), and you get something that actually works.
It's like the difference between trying to fertilize a dead garden versus watering one that just needs a little help.
What This Means for Patients (and for Scholar Rock)
SMA affects roughly 1 in 10,000 births, making it rare but not vanishingly so. Newborn screening programs have expanded access to early treatment, but a significant population of older children and adults live with substantial disability despite being on gene-targeted therapy. Those are the patients Isembyld is designed to help.
The approval label is notably broad: ages 2 through adulthood. That's significant in a field where many treatments were originally tested only in infants. It means a teenager on Spinraza who's been slowly losing function, or an adult on Evrysdi who plateaued years ago, now has a new option to layer on top.
For Scholar Rock, this is a defining moment. The company bet its pipeline on an approach that the broader industry had largely given up on. It navigated a regulatory path that included preparing two independent fill-finish manufacturing facilities to avoid supply-related delays; a level of operational paranoia that paid off.
Pricing and analyst forecasts haven't been publicly detailed yet, but the rare disease designation, the monthly infusion schedule, and the complementary (not competitive) positioning relative to existing therapies suggest Scholar Rock is entering a market where it doesn't have to steal patients from anyone. It just has to convince doctors that their current regimen isn't enough on its own.
Given that SMA patients are still declining on existing treatments, that shouldn't be a hard sell.
4 min read
J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It.
A federal court just blocked generic Spravato until 2035, handing J&J a decade of exclusivity on a drug headed toward $5 billion in peak sales. For generics companies, the ruling is a costly warning shot.
